Articles related to PANCREATIC CANCER

Abdominal cancer is no longer an ailment confined to older demographics, with a notable uptick in cases among younger adults. Physicians are urged to consider early screening, especially for patients with familial cancer histories, amidst growing concerns over lifestyle and environmental influences.

The FDA’s approval of irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin marks a pivotal advancement in first-line treatment options for metastatic pancreatic adenocarcinoma, showcasing a notable increase in overall and progression-free survival rates.

In a recent phase II trial, patients with untreated metastatic pancreatic ductal adenocarcinoma receiving sequential nab-P/Gem-mFOLFOX experienced a median overall survival of 13.2 months, compared to 9.7 months in those receiving standard nab-P/Gem treatment, indicating a notable improvement in survival outcomes.

Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.

Explore innovative options for patients with pancreas, liver and biliary cancers at the Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023.

Take part in an engaging multidisciplinary discussion on the evolving dynamics of hepato-pancreatico-biliary cancers. Discover, learn, and prepare to integrate these new strategies into your clinical practice.